Dapagliflozin: A Sodium-Glucose Co-Transporter-2 Inhibitor

Introduction to Dapagliflozin

Dapagliflozin is part of a newer class of medications known as sodium-glucose co-transporter-2 (SGLT2) inhibitors, which are utilized in the management of type 2 diabetes mellitus. These drugs effectively lower blood glucose levels by inhibiting the reabsorption of glucose in the kidneys.

Clinical Benefits Beyond Diabetes

Clinical trials involving SGLT2 inhibitors have shown not only their efficacy in treating type 2 diabetes but also their beneficial effects on cardiovascular health. With these cardiovascular advantages in mind, researchers at the University of Glasgow investigated whether dapagliflozin could also benefit patients with cardiovascular disease, regardless of their diabetes status.

Phase 3 Clinical Trial Findings

The findings from their Phase 3 clinical trial were published in *The New England Journal of Medicine*. The study included 4,744 patients diagnosed with heart failure characterized by a reduced ability of the heart to pump blood. Notably, 45% of these participants also had type 2 diabetes.

Study Design

The trial employed a placebo-controlled design, where participants were randomly assigned to receive either dapagliflozin (10 mg once daily) or a placebo, in addition to their standard treatment regimen. Researchers monitored participants for any signs of worsening heart failure, including hospitalizations, urgent treatments for heart failure, or cardiovascular-related deaths.

Results of the Trial

Over an average follow-up period of 18 months, results indicated that the incidence of worsening heart failure was lower in the dapagliflozin group (16.3%) compared to the placebo group (21.2%). This represents a 26% reduction in the risk of heart failure among patients treated with dapagliflozin.

Additional Findings

Further analyses revealed that dapagliflozin treatment led to a 30% reduction in the risk of a first worsening heart failure event and an 18% decrease in the risk of death due to cardiovascular causes.

Adverse Effects

Common adverse effects associated with dapagliflozin included dehydration, low blood pressure, fainting, kidney dysfunction, and low blood sugar levels. These side effects were reported in approximately 7% of study participants, with no significant difference in frequency between the two groups.

Expert Insights

Professor McMurray, the study’s lead investigator, noted, “Adverse events rarely required the discontinuation of treatment. There was no notable excess of any serious adverse event in the dapagliflozin group.”

Significance of Findings

The reduced risk of heart failure associated with dapagliflozin was consistent across both diabetic and non-diabetic patients. Professor McMurray emphasized, “The most important finding of all is the benefit in patients without diabetes. This shows dapagliflozin is truly a treatment for heart failure and not just a drug for diabetes.” He concluded that the trial demonstrates dapagliflozin’s ability to reduce mortality and hospitalization rates while enhancing overall quality of life for patients with heart failure, regardless of diabetes status.

Clinical Implications

The implications of these findings are significant, as few drugs achieve similar results in heart failure management. Dapagliflozin’s effectiveness alongside standard therapies positions it as a promising option for improving patient outcomes.

References

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Sep 19.

Press release retrieved from https://www.eurekalert.org/pub_releases/2019-09/d-nrs091919.php

Information on dapagliflozin can be found at https://www.diabetes.co.uk/diabetes-medication/sglt2-inhibitors.html.